ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Detection of OXA-23-producing Proteus mirabilis in Switzerland.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genomic insights into one carbapenem-resistant and multidrug-resistantMicrobiology spectrum · 2026Article
- Detection of blaEmerging infectious diseases · 2026Article
- Tackling Drug Resistance and Virulence inThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Dissemination of OXA-23 carbapenemase-producingMicrobial genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteus mirabilis is a Gram-negative bacterium found in the environment and also forms part of the commensal flora in the gastrointestinal tract of both humans and animals. P. mirabilis can cause a wide variety of infections, however it does not harbor any intrinsic β-lactamase genes and as such usually exhibits full susceptibility to β-lactams with the exception of imipenem, to which it is naturally resistant. OXA-23 enzymes are carbapenem-hydrolyzing class D β-lactamases and are usually the main cause of acquired resistance to carbapenems in Acinetobacter baumannii but have recently been reported in P. mirabilis in France. In this report we describe the emergence of OXA-23-producing P. mirabilis clinical isolates from Switzerland.
Indexed as
Identifiers
39708275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.